Joseph Michael Fitzgerald sold $4.9M of BSX
EVP & Group Pres, Cardiology at BOSTON SCIENTIFIC CORP. 50,000 shares at an average of $98.47, traded Oct 1, 2025, filed Oct 1, 2025.
Score components
- +15RoleOfficer
- +25Trade size$4.9M at market
- +5Share of holdings soldSold 22% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.1%, 3m -0.5%, 6m -35.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001225208-25-008180, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2025 | MOption exercise Common Stock10b5-1 | +50,000 | $26.15 | $1.3M | 228,342 | Oct 1, 2025 |
| Oct 1, 2025 | SOpen-market sale Common Stock10b5-1 | -8,245 | $98.91 | $815k | 220,097 | Oct 1, 2025 |
| Oct 1, 2025 | SOpen-market sale Common Stock10b5-1 | -41,755 | $98.38 | $4.1M | 178,342 | Oct 1, 2025 |
| Oct 1, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -50,000 | $0.00 | $0 | 50,000 | Oct 1, 2025 |
Related signals
Other insiders at BOSTON SCIENTIFIC CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | BSXbuy BOSTON SCIENTIFIC CORP | Susan E Morano director | $100k 2,040 shares | +17% | |
| 56Moderate | BOSTON SCIENTIFIC CORP | David C Habiger director | $100k 2,100 shares | +14% | |
| 76Notable | BOSTON SCIENTIFIC CORP | Michael F Mahoney Chairman, President & CEO | $9.0M 186,240 shares | +13% | |
| 53Moderate | BOSTON SCIENTIFIC CORP | David C Habiger director | $57k 1,182 shares | +9% | |
| 69Notable | BOSTON SCIENTIFIC CORP | Edward J Ludwig director | $227k 5,000 shares | +20% | |
| 67Notable | BOSTON SCIENTIFIC CORP | David C Habiger director | $251k 4,450 shares | +47% | |
| 63Notable | BOSTON SCIENTIFIC CORP | Edward J Ludwig director | $203k 3,580 shares | +16% | |
| 66Notable | BOSTON SCIENTIFIC CORP | Cheryl Pegus director | $100k 1,770 shares | - | |
| 20Weak | BOSTON SCIENTIFIC CORP | Michael F Mahoney Chairman, President & CEO | $15M 160,901 shares | -10% | |
| 25Weak | BOSTON SCIENTIFIC CORP | Arthur C Butcher EVP& Grp Pres, MedSurg & APAC | $1.8M 17,313 shares | -42% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.